LOVFF (Cannara Biotech) Moat Score: 2/10 (As of Jul. 02, 2026)


LOVFF Cannara Biotech Inc LOVFF
84 GF Score
Price $1.18
GF Value $1.18
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Cannara Biotech Moat Score?

Cannara Biotech LOVFF -4.84% 84 Moat Score is 2 as of Jul. 02, 2026. GuruFocus rates LOVFF with a GF Score™ of 84/100 and a GF Value™ of $1.18 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,031 Drug Manufacturers companies, Cannara Biotech ranks better than 81.67% on this metric.

Cannara Biotech has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Cannara Biotech has No Moat: Cannara Biotech lacks significant market leadership and customer loyalty. The company does not have strong intellectual property or regulatory barriers, and its cost advantages are not durable, resulting in a weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Cannara Biotech might have No Moat - Very weak/transient advantages.

Cannara Biotech  (OTCPK:LOVFF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Cannara Biotech Moat Score Related Terms

LOVFF vs ZTS, UTHR: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cannara Biotech Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's Moat Score distribution charts can be found below:

* The bar in red indicates where Cannara Biotech's Moat Score falls into.


LOVFF
84GF Score
Cannara Biotech Inc LOVFF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Cannara Biotech (LOVFF) has a Moat Score of 2 as of Jul. 02, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Cannara Biotech ranks #189 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 18.3%.
Is Cannara Biotech's Moat Score too high?
Cannara Biotech's current Moat Score is 2. Based on the distribution chart, Cannara Biotech ranks #189 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cannara Biotech has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cannara Biotech's Moat Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cannara Biotech ranks #189 out of 1031 companies for Moat Score. This places Cannara Biotech in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Cannara Biotech's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannara Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cannara Biotech (LOVFF) is currently considered Fairly Valued. The stock's GF Value™ is $1.18, compared to a current price of $1.18 — trading right at its estimated fair value. The current Moat Score is 2. Cannara Biotech's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Cannara Biotech (LOVFF), the current Moat Score is 2 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cannara Biotech (LOVFF) Overvalued in 2026?

Based on GuruFocus' analysis, Cannara Biotech stock appears to be undervalued. The current stock price of $1.18 is trading 0% below its estimated GF Value™ of $1.18. GuruFocus considers Cannara Biotech to be Fairly Valued.

Key valuation signals for LOVFF:

  • Moat Score: 2
  • GF Value™: $1.18 vs. price of $1.18 (0% below fair value)
  • GF Score™: 84/100 with 4 warning signs

No single metric tells the full story. See the LOVFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cannara Biotech Business Description

Other Exchanges 8CB0:GermanyLOVE:Canada
Address 1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
84GF Score

Get the complete analysis for LOVFF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.18
Price
$1.18
GF Value